Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors.
Phase 1 Clinical Study Expected to Begin in H2 2024.
ALAMEDA, Calif. and TAIPEI, Feb. 5, 2024 /… อ่านเพิ่ม